Cells (Nov 2021)

The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval

  • Mariana Matias,
  • Jacinta O. Pinho,
  • Maria João Penetra,
  • Gonçalo Campos,
  • Catarina Pinto Reis,
  • Maria Manuela Gaspar

DOI
https://doi.org/10.3390/cells10113088
Journal volume & issue
Vol. 10, no. 11
p. 3088

Abstract

Read online

Melanoma is recognized as the most dangerous type of skin cancer, with high mortality and resistance to currently used treatments. To overcome the limitations of the available therapeutic options, the discovery and development of new, more effective, and safer therapies is required. In this review, the different research steps involved in the process of antimelanoma drug evaluation and selection are explored, including information regarding in silico, in vitro, and in vivo experiments, as well as clinical trial phases. Details are given about the most used cell lines and assays to perform both two- and three-dimensional in vitro screening of drug candidates towards melanoma. For in vivo studies, murine models are, undoubtedly, the most widely used for assessing the therapeutic potential of new compounds and to study the underlying mechanisms of action. Here, the main melanoma murine models are described as well as other animal species. A section is dedicated to ongoing clinical studies, demonstrating the wide interest and successful efforts devoted to melanoma therapy, in particular at advanced stages of the disease, and a final section includes some considerations regarding approval for marketing by regulatory agencies. Overall, considerable commitment is being directed to the continuous development of optimized experimental models, important for the understanding of melanoma biology and for the evaluation and validation of novel therapeutic strategies.

Keywords